Bevacizumab is an attractive option for metastatic renal cell carcinoma because of the correlation between VEGF and von Hippel Lindau (VHL) tumor suppressor gene, which has a substantial role in the mechanism of the disease. Here, VEGFA is linked to neoplasm.